p150/95 (CD11c/CD18) Expression Is Required for the Development of Experimental Autoimmune Encephalomyelitis
Authors:
- Scott R. BarnumSBScott R. Barnum
- 1 June 2007
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 170 (6) , 2001-2008
Abstract
No abstract availableKeywords
Funding Information
- National Multiple Sclerosis Society (RG-3437-A-6)
- National Institutes of Health (GM08111-18, NS46032, RR017009)
This publication has 59 references indexed in Scilit:
- Disruption of the β2-integrin CD11d (αDβ2) gene fails to protect against experimental autoimmune encephalomyelitisJournal of Neuroimmunology, 2007
- Molecular mechanisms involved in T cell migration across the blood–brain barrierJournal of Neural Transmission, 2006
- Natalizumab and PMLNature Neuroscience, 2005
- Comparison of effects of methylprednisolone and anti-CD11d antibody treatments on autonomic dysreflexia after spinal cord injuryExperimental Neurology, 2005
- Progressive Multifocal Leukoencephalopathy in a Patient Treated with NatalizumabNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple SclerosisNew England Journal of Medicine, 2005
- Microglial cell activation and proliferation precedes the onset of CNS autoimmunityJournal of Neuroscience Research, 2005
- Heterogenous glycosylation of ICAM‐3 and lack of interaction with Mac‐1 and p150,95European Journal of Immunology, 1995
- Regulated expression and function of CD11c/CD18 integrin on human B lymphocytes. Relation between attachment to fibrinogen and triggering of proliferation through CD11c/CD18.Journal of Experimental Medicine, 1991
- Stimulated mobilization of monocyte Mac-1 and p150,95 adhesion proteins from an intracellular vesicular compartment to the cell surface.Journal of Clinical Investigation, 1987